The short version of thymus extract fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-07-28. Anything still debated is marked as such rather than presented as settled.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Acetylated peptide | N-terminal acetyl group blocks aminopeptidase attack |
| Residue count | 28 amino acids | Matches the N-terminus of prothymosin alpha |
| Molecular mass | About 3,108 Da | Value for the free, unmodified peptide |
| Isoelectric point | Approximately 4.2 | Acidic; net negative charge at neutral pH |
| Encoding gene | PTMA | Human gene for the precursor protein |
Stability depends on temperature, pH, and the number of freeze-thaw events the sample has experienced. Freeze-dried material is commonly held at -20 °C or colder, while reconstituted liquid is kept cold and used within a short window. Extreme pH and prolonged light exposure can promote deamidation, oxidation, or aggregation, particularly at asparagine and methionine positions. Adsorption to container walls can lower the measured concentration of a dilute solution even when the peptide molecules themselves remain intact.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or chemically modified byproducts. Mass spectrometry confirms the expected molecular mass and can indicate acetylation state or sequence errors. Amino acid analysis and peptide mapping supply complementary sequence-level information, while endotoxin testing is relevant for preparations intended for cell or animal work. Purity figures reported by suppliers refer to the method used and are not directly comparable across laboratories unless conditions are stated.
Lyophilized material is typically treated as a hygroscopic solid that should be brought to room temperature before the container is opened, which limits condensation on the powder. Reconstitution is commonly done with sterile water or a buffered diluent, and gentle mixing is preferred over vigorous agitation to reduce foaming and surface adsorption. Because peptides can bind to plastic and glass, diluents containing a small amount of carrier protein are sometimes used in laboratory work. Working solutions are generally aliquoted and prepared fresh rather than subjected to repeated freezing and thawing.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
== Victim == Buzhu's father emigrated to the Netherlands from Morocco in the 1950s and worked in a Dutch mine. His mother later rejoined his father and the couple settled in Utrecht. The father then opened a butcher shop in Amsterdam and provided financial stability to the family. After his father died, Buzhu went into organized crime alongside other Moroccans who had emigrated to the Netherlands. In order to hide his illicit wealth, Buzhu pretended his money was earned through real estate investment. His real source of income was smuggling large quantities of drugs from Morocco. In the 1990s, he was convicted by Dutch police of possession of illegal firearms and participating in torture. On 24 June 2015, a friend of Buzhu's went to the police in Driebergen claiming he found a tracking beacon underneath his vehicle. Buzhu also came forward and claimed that the case was related to the kidnapping of coffee shop owner in 2009. The police closed the case without a thorough investigation. A few days later, he returned to the police station and filed a complaint against Ridouan Taghi and his right-hand man Saïd Razzouki for death threats. Further investigations led Buzhu to identify several organized criminals in the Dutch drug trade, with his statements giving rise to the 26Koper investigation. In 2016 his friend Ranko Scekic and another friend were the victims of an attempted assassination in Utrecht by Taghi's hitmen for their allegiance with Buzhu. The assassination was eventually called off due to heavy police presence in the neighborhood.
=== Historical Use of Insects in Medicine === The medicinal application of insects dates back to ancient civilizations. The Smithsonian Institution has documented historical uses of insects such as the utilization of bee venom therapy in Egyptian medicine for treating arthritis and joint pain. Ancient Greek and Roman physicians, including Galen, recorded the use of insects like cantharidin from blister beetles for dermatological conditions. In medieval Europe powdered insects were included in remedies for various ailments including infections and respiratory disorders.
Nicotinamide (INN, BAN UK) or niacinamide (USAN US) (IUPAC name: 3-pyridinecarboxoamide) is a form of vitamin B3 found in food and used as a dietary supplement and medication. As a supplement, it is used orally (swallowed by mouth) to prevent and treat pellagra (niacin deficiency). While nicotinic acid (niacin) may be used for this purpose, nicotinamide has the benefit of not causing skin flushing. As a cream, it is used to treat acne, and has been observed in clinical studies to improve the appearance of aging skin by reducing hyperpigmentation and redness. It is a water-soluble vitamin. Clinical trials have shown promise in protecting eye health, particularly in the context of glaucoma. It is believed to support the health of retinal ganglion cells and may help protect against glaucoma-related damage. Nicotinamide has been studied for its potential neuroprotective effects. While some clinical trials have demonstrated improvements in visual fields and retinal function, it is not yet approved for the treatment of glaucoma. The use of nicotinamide should be approached with caution, especially at high doses, due to the risk of liver injury. Ongoing research continues to explore the full potential of nicotinamide in eye protection and its role in managing eye conditions. Side effects are minimal. At high doses, liver problems may occur. Normal amounts are safe for use during pregnancy. Nicotinamide is in the vitamin B family of medications, specifically the vitamin B3 complex. It is an amide of nicotinic acid.
In February 2020, Marguerite Stern, alongside Christine Delphy and Fatiha Agag-Boudjahlat, co-signed a column written by Pauline Arrighi entitled "Trans: suffit-il de s'autoproclamer femme pour pouvoir exiger d'être considéré comme telle?" ("Trans: is it enough to proclaim oneself a woman to be able to demand to be considered as such"). This column was initially published in HuffPost and later taken town the editorial staff, who described it as transphobic. It was later republished by Marianne. On February 26, 2020, several personalities and associations signed two columns in Libération entitled "Féminisme: le débat sur la place des femmes trans n'a pas lieu d'être" ("Feminism: the debate on the place of trans women has no place") and "À toi ma sœur, mon frère, mon adelphe" ("To you my sister, my brother, my sibling"). These opposed pieces crystallized the ongoing dissension within the collage movement over transgender rights. Marguerite Stern was harassed for her positions, and received death threats, which led to psychiatric hospitalization for generalized anxiety disorder. In September 2021, seven authors responded to these views by withdrawing from a feminist book fair due to Stern and fellow activist Dora Moutot's participation. In August 2022, she co-signed with Dora Moutot a column published in Marianne addressed to Élisabeth Borne, in which they opposed a Planned Parenthood poster with a pregnant transgender man, stating that "it uses vocabulary used by transactivists".
Campbell and Satoshi Ōmura; she received it "for her discoveries concerning a novel therapy against Malaria". 2015: American inventor and clean water advocate Deepika Kurup invented a photocatalytic composite material that removes 100% of faecal coliform bacteria from contaminated water. Deepika won the Discovery Education 3M Young Scientist Challenge award and The US Stockholm Junior Water Prize for her work. 2015: Asha de Vos became the first Sri Lankan person to receive a PhD in marine mammal research, completing her thesis on "Factors influencing blue whale aggregations off southern Sri Lanka" at the University of Western Australia. 2016: American geophysicist Marcia McNutt became the first female president of the American National Academy of Sciences. 2016: French-Algerian particle physicist Yasmine Amhis was awarded the Jacques Herbrand Prize given by the French Academy of Sciences 2018: British astrophysicists Hiranya Peiris and Joanna Dunkley and Italian cosmologist Licia Verde were among 27 scientists awarded the Breakthrough Prize in Fundamental Physics for their contributions to "detailed maps of the early universe that greatly improved our knowledge of the evolution of the cosmos and the fluctuations that seeded the formation of galaxies". 2018: British astrophysicist Jocelyn Bell Burnell received the special Breakthrough Prize in Fundamental Physics for her scientific achievements and "inspiring leadership", worth $3 million.
Sources: en.wikipedia.org
=== Shelf life === The shelf life of canned evaporated milk varies according to both its added content and its proportion of fat. For the regular unsweetened product, a shelf life of 15 months may be expected before any noticeable destabilization occurs.
== Development and patents == D-Ribose-L-cysteine was developed by Herbert T. Nagasawa, a medicinal chemist formerly affiliated with the United States Department of Veterans Affairs and the University of Minnesota, whose research focused on sulfur amino acid metabolism and hepatic toxicology. The compound and its use as a glutathione-enhancing agent are protected by multiple patents, including United States Patent US 9,173,917 B2, assigned to Max International and the U.S. Department of Veterans Affairs. D-Ribose-L-cysteine has since been incorporated into dietary supplement formulations marketed by Max International, Inc. and LiveMax, LLC.
=== Sexual dysfunction === Activation of 5-HT2C receptor subtype has been reported to mediate numerous effects, such as penile erection. Based on multiple studies, results show that several 5-HT2C receptor agonists, including mCPP and YM348 induce penile erections in rats, but mCPP seems to mimic both vasodilation and vasoconstriction. The vasodilator action is mediated by 5-HT1D receptors, whereas the vasoconstriction effect involves 5-HT2 receptor activation. YM-348 is a highly selective 5-HT2C agonist and results show that YM348 can induce penile erections and hypolocomotion (induced at a high dose) in rats, as did other 5-HT2C receptor agonists. These effects were completely inhibited by a selective 5-HT2C receptor antagonist, SB-242,084. Therefore, results suggest that YM348 is a potent and orally active 5-HT2C receptor agonist.
Due to the arrangement of the receiver antennas, the sensitive area had a number of side lobes that allowed reception at multiple vertical angles. Typically the operator would use the upper set of antennas at 215 ft (66 m), which had the clearest view of the horizon. Due to the half-wave interference from the ground, the main lobe from this antenna was directed at about 2.5 degrees above the horizontal, with its sensitive region extending from about 1 to 3 degrees. At the ground the gain was zero, which allowed aircraft to escape detection by flying at low altitudes. The second lobe extended from about 6 to 12 degrees, and so on. This left a distinct gap in the reception pattern centred at about 5.2 degrees. This reception pattern provided CH with a relatively accurate way to estimate the altitude of the target. To do this, the motorized switch in the receiver hut was used to disconnect the four receiver masts and instead select the two vertically displaced antennas on one mast. When connected to the radiogoniometer, the output on the display was now effected by the relative signal strength of the two lobes, rather than the relative strengths in X and Y in the horizontal plane. The operator swung the radiogoniometer looking for the peak or minimum reception, as before, and noted the angle. The number reported by the operator was the line-of-sight range to the target, or slant range, which included components of both the horizontal distance and altitude.
Sources: en.wikipedia.org
===== MeSH D08.811.913.555 – one-carbon group transferases (EC 2.1) ===== MeSH D08.811.913.555.150 – amidinotransferases MeSH D08.811.913.555.275 – carboxyl and carbamoyl transferases MeSH D08.811.913.555.275.200 – aspartate carbamoyltransferase MeSH D08.811.913.555.275.600 – ornithine carbamoyltransferase MeSH D08.811.913.555.400 – hydroxymethyl and formyl transferases MeSH D08.811.913.555.400.100 – aminomethyltransferase MeSH D08.811.913.555.400.300 – glutamate formimidoyltransferase MeSH D08.811.913.555.400.500 – glycine hydroxymethyltransferase MeSH D08.811.913.555.400.625 – phosphoribosylaminoimidazolecarboxamide formyltransferase MeSH D08.811.913.555.400.750 – phosphoribosylglycinamide formyltransferase MeSH D08.811.913.555.500 – methyltransferases MeSH D08.811.913.555.500.100 – acetylserotonin n-methyltransferase MeSH D08.811.913.555.500.175 – betaine-homocysteine S-methyltransferase MeSH D08.811.913.555.500.250 – catechol O-methyltransferase MeSH D08.811.913.555.500.350 – dna modification methylases MeSH D08.811.913.555.500.350.500 – dna (cytosine-5-)-methyltransferase MeSH D08.811.913.555.500.350.700 – site-specific dna-methyltransferase (adenine-specific) MeSH D08.811.913.555.500.350.850 – site-specific dna methyltransferase (cytosine-specific) MeSH D08.811.913.555.500.387 – glycine N-methyltransferase MeSH D08.811.913.555.500.425 – guanidinoacetate N-methyltransferase MeSH D08.811.913.555.500.500 – histamine N-methyltransferase MeSH D08.811.913.555.500.625 – homocysteine S-methyltransferase MeSH D08.811.913.555.500.645 – 5-methyltetrahydrofolate-homocysteine s-methyltransferase MeSH D08.811.913.555.500.650 – nicotinamide N-methyltransferase MeSH D08.811.913.555.500.700 – phenylethanolamine N-methyltransferase MeSH D08.811.913.555.500.710 – phosphatidyl-N-methylethanolamine N-methyltransferase MeSH D08.811.913.555.500.712 – phosphatidylethanolamine N-methyltransferase MeSH D08.811.913.555.500.800 – protein methyltransferases MeSH D08.811.913.555.500.800.400 – histone-lysine n-methyltransferase MeSH D08.811.913.555.500.800.650 – o-6-methylguanine-DNA methyltransferase MeSH D08.811.913.555.500.800.750 – protein-arginine n-methyltransferase MeSH D08.811.913.555.500.800.800 – protein o-methyltransferase MeSH D08.811.913.555.500.800.800.700 – protein d-aspartate-l-isoaspartate methyltransferase MeSH D08.811.913.555.500.862 – thymidylate synthase MeSH D08.811.913.555.500.925 – trna methyltransferases
Afterwards, Adler takes extended time away from work, eventually revealing to Eric that he has a malignant brain tumor, and may not live longer than a year. As Pierpoint faces a debt crisis stemming from its ESG pivot, Adler clashes with senior leadership, particularly CFO Wilhelmina Fassbinder, over a potential sale of the firm, and brokers a meeting with Mitsubishi executives. Eric, realizing he needs to break free from Adler's influence, exploits Adler's illness during the meeting by gaslighting him into believing he overlooked a major error in the deal sheet. Adler has a breakdown and reveals his prognosis to the room; Eric escorts him out, and Adler realizes Eric betrayed him. Six months later, Adler has died, with Pierpoint organizing his memorial.
== Controversy == The 2014 summary policy statement of the American Academy of Pediatrics (AAP) makes no specific mention of bottle feeding, but makes clear that "[b]reastfeeding and human milk are the normative standards for infant feeding and nutrition", and refers to decisions regarding the supply of infant nutrition as "a public health issue and not only a lifestyle choice… [g]iven the documented short- and long-term medical and neurodevelopmental advantages of breastfeeding". The AAP policy recommends breastfeeding exclusively for six months, continuing it with introduction of complementary foods, with an overall duration of "1 year or longer as mutually desired by mother and infant". The body of the policy statement notes and cites literature indicating that, in addition to the importance of mother's milk, the manner of the food delivery has implications: that "breastfed infants self-regulate intake volume", whereas bottle-fed infants receiving expressed breast milk or formula have "increased bottle emptying, poorer self-regulation, and excessive weight gain in late infancy", and that such early practice of self-regulation correlate with adult patterns of weight gain (ibid.). The AAP policy notes that "[m]edical contraindications to breastfeeding are rare". The transmission of some viral diseases through breastfeeding is reportedly preventable, e.g., by expressing breast milk and subjecting it to Holder pasteurization.
active site Also binding site and catalytic site. The region of an enzyme to which one or more substrate molecules bind, causing the substrate or another molecule to undergo a chemical reaction. This region usually consists of one or more amino acid residues (commonly three or four) which, when the enzyme is folded properly, are able to form temporary chemical bonds with the atoms of the substrate molecule; it may also include one or more additional residues which, by interacting with the substrate, are able to catalyze a specific reaction involving the substrate. Though the active site constitutes only a small fraction of all the residues comprising the enzyme, its specificity for particular substrates and reactions is responsible for the enzyme's biological function.
Four classes of mutations are (1) spontaneous mutations (molecular decay), (2) mutations due to error-prone replication bypass of naturally occurring DNA damage (also called error-prone translesion synthesis), (3) errors introduced during DNA repair, and (4) induced mutations caused by mutagens. Scientists may sometimes deliberately introduce mutations into cells or research organisms for the sake of scientific experimentation. One 2017 study claimed that 66% of cancer-causing mutations are random, 29% are due to the environment (the studied population spanned 69 countries), and 5% are inherited. Humans on average pass 60 new mutations to their children but fathers pass more mutations depending on their age with every year adding two new mutations to a child.
Sources: en.wikipedia.org
Thymosin fraction 5 is a mixture of many peptides obtained from thymus tissue, while thymosin alpha 1 is a single defined 28-residue molecule. The two names appear together in older literature because the purified peptide was first obtained from that mixture.
The precursor, prothymosin alpha, is encoded by the PTMA gene in humans. The 28-residue peptide corresponds to the N-terminal segment released from that larger protein.
It is produced as a fragment of prothymosin alpha and is present in many tissues. Circulating concentrations are low, which makes routine measurement difficult.
It is usually described as an immunomodulatory peptide rather than a classic circulating hormone. No endocrine gland is known to release it as a primary secretory product, and its measured presence in blood is not firmly established.